Invivogen
Menu

Jurkat-Raji ICOS/ICOS-L assay (Bio-IC™)

Product Unit size Cat. code Docs. Qty. Price

ICOS/ICOS-L Bio-IC™

2 cell lines (Jurkat & Raji) based Lucia luciferase reporter assay

Show product

3-7 x 10e6 cells (x2)

rajkt-hicos
+-
$3,355
You may also need : Blasticidin | View more associated products

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

 

Antagonist screening assay for ICOS/ICOS-L axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule antagonists of the ICOS/ICOS-L immune checkpoint (IC) axis. This assay is comprised of:

PPrinciple of ICOS/ICOS-L cellular assay
Principle of ICOS/ICOS-L cellular assay
(click to enlarge)

  • Jurkat-Lucia™-hICOS: Reporter T cells
  • Raji-hICOS-L: Antigen-presenting cells (APCs)

​These paired cell lines allow the mimicking of the immune synapse between T cells and APCs through the interaction of cell surface molecules delivering T-cell activation signals.

Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in  CD4 and CD8 T cells upon their activation, whereas its ligand ICOS-L (CD275), is mostly expressed by APCs [1]. 

More details More details

 

Assay principle:

This assay relies on the co-culture of Jurkat-Lucia™-ICOS and Raji-hICOS-L cells.
Jurkat-Lucia™-ICOS cells express a hICOS-CD3ζ fusion protein along with the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. CD3ζ is a key component of the T-cell receptor (TCR) and CD3 complex that triggers TCR downstream signaling.
Raji-hICOS-L cells express the ICOS-L activating IC ligand.
In the presence of a potent ICOS or ICOS-L antagonist, the ICOS-CD3ζ-mediated activation is blocked and there is no Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).

T-cell key features:

  • Stable hICOS-CD3ζ expression
  • NFAT-inducible Lucia luciferase reporter activity

APC key features:

  • Stable hICOS-L overexpression

 

InvivoGen also offers Jurkat-Lucia™-hICOS cells without Raji-hICOS-L cells to measure the potency of agonists of the ICOS/ICOS-L axis.

 

Read our review Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies Learn more about Immune Checkpoint Antibodies.

 

Reference:

1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.

Figures

ICOS overexpression on Jurkat-Lucia™ hICOS cells
ICOS overexpression on Jurkat-Lucia™ hICOS cells

Validation of human ICOS overexpression by Jurkat-Lucia™hICOS cells. Jurkat-Lucia™ hICOS and Jurkat-Lucia™ NFAT cells were incubated with a PE‑conjugated Anti-hICOS mAb for 30 minutes. The binding affinity was measured using flow cytometry. Unstained Jurkat-Lucia™ hICOS cells are shown in grey.

ICOS-L overexpression on Raji-hICOS-L cells
ICOS-L overexpression on Raji-hICOS-L cells

Validation of human ICOS-L overexpression by Raji-hICOS-L cells. Raji-hICOS-L and Raji-Null cells were incubated with a PE‑conjugated Anti-hICOS-L mAb for 30 minutes. The binding affinity was measured using flow cytometry. Unstained Raji-hICOS-L cells are shown in grey.

Disruption of ICOS/ICOS-L activatory activation
Disruption of ICOS/ICOS-L activatory activation

Activation of Jurkat-Lucia™-hICOS cells. Raji-hICOS-L and Jurkat-Lucia™-hICOS cells were incubated with gradient concentrations of antagonist Anti-hICOS-L hIgG2, antagonist Anti-h/mICOS mIgG2a, or control Anti-β-Gal hIgG1 monoclonal antibodies for 6 hours. NFAT activation in the Jurkat-Lucia™-hICOS cells, reflecting the interaction of ICOS-L with the ICOS-CD3ζ fusion protein was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4 Reagent. Percentages of the maximal responses are shown (mean + SEM).

Back to the top

Specifications

Growth medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml Normocin™

Antibiotic resistance:

Quality Control:

  • Human ICOS and ICOS-L expression have been verified by flow-cytometry.
  • Reporter activity has been validated following the co-culture of the two cell lines.
  • The stability for 20 passages following thawing has been verified.
  • Both cell lines are guaranteed mycoplasma-free.
     

These products are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

Please note: Both cell lines are sold together.

  • 3-7 x 106 Jurkat-Lucia™ -hICOS cells in a cryovial or shipping flask
  • 3-7 x 106 Raji-hICOS-L cells in a cryovial or shipping flask
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of Zeocin® (100 mg/ml)
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.
  • 1 tube of QUANTI-Luc™ 4 Reagent, a Lucia luciferase detection reagent (sufficient to prepare 25 ml)

Shipped on dry ice Shipped on dry ice (Europe, USA, Canada, and some areas in Asia)

Back to the top

Details

Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in  CD4+ and CD8+ T cells upon their activation, whereas its ligand ICOS-L (also known as CD275), is mostly expressed by antigen-presenting cells [1]. The interaction between ICOS and ICOS-L delivers a secondary co-stimulatory signal through the activation of the transcription factor AKT, which promotes T cell proliferation and differentiation as well as the production of cytokines  [1]. In tumor immunity, ICOS is involved in the amplification of the anti-tumor cytotoxic CD8+ T cell response, as well as the 'pro-tumor' function and maintenance of regulatory T cells (Tregs). Therefore, both agonistic and antagonistic monoclonal antibodies (mAbs) targeting this pathway are being investigated in combinational cancer immunotherapy [2]. Notably, ICOS agonistic mAbs have been shown to potentiate the effects of anti-CTLA-4 mAbs [3]. 

 

References:

1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.
2. Solinas, C. et al. 2020. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open 5.
3. Soldevilla, M.M. et al. 2019. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Mol Ther 27, 1878-1891.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top
Customer Service
& Technical Support
Shopping cart is empty